Anti-ganglioside(GD) 2 monoclonal antibodies have been widely used in clinical practice and can significantly improve the prognosis of children with high-risk neuroblastoma(HR-NB) and refractory/relapsed neuroblastoma(R/R NB). However, some patients still experience relapse, and a few develop severe treatment-related adverse reactions. Therefore, there is an urgent need to optimize GD2-targeted antibodies or explore new therapeutic targets to increase the cure rate of NB. This paper reviewed three aspects: the clinical application progress of GD2-related antibodies, the development of GD2 antibody-drug conjugates, and the research advances in novel antibody drugs for NB,aiming to provide references for clinical practice.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |